Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern …

HS Hochster, E Weller, RD Gascoyne, TS Ryan… - Blood, 2005 - Elsevier
E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …
被引用次数：154 相关文章 所有 4 个版本
[PDF] ascopubs.org

Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study

E Bachy, JF Seymour, P Feugier, F Offner… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The PRIMA study (ClinicalTrials. gov identifier: NCT00140582) established that 2
years of rituximab maintenance after first-line immunochemotherapy significantly improved …
被引用次数：236 相关文章 所有 8 个版本
[HTML] nih.gov

Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial …

C Taverna, G Martinelli, F Hitz, W Mingrone… - Journal of clinical …, 2016 - ascopubs.org
Purpose Rituximab maintenance therapy has been shown to improve progression-free
survival in patients with follicular lymphoma; however, the optimal duration of maintenance …
被引用次数：71 相关文章 所有 9 个版本
[HTML] sciencedirect.com

[HTML][HTML] Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline …

GA Salles, JF Seymour, P Feugier, F Offner… - Blood, 2013 - Elsevier
Abstract The intergroup PRIMA Phase III study was designed to investigate the potential
benefit of 2-years of rituximab maintenance in patients with follicular lymphoma (FL) …
被引用次数：97 相关文章 所有 5 个版本

Follicular lymphoma, survival, and rituximab: is it time to declare victory?

SJ Horning - Journal of Clinical Oncology: Official Journal of the …, 2008 - europepmc.org
Follicular lymphoma, survival, and rituximab: is it time to declare victory? - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …
被引用次数：32 相关文章 所有 6 个版本
[HTML] haematologica.org

[HTML][HTML] Rituximab maintenance therapy: a step forward in follicular lymphoma

MHJ van Oers - Haematologica, 2007 - haematologica.org
Whilst recent advances in the treatment of follicular lymphoma (FL) have improved the
outlook for many patients, relapses still occur and the search continues for strategies to …
被引用次数：38 相关文章 所有 9 个版本
[HTML] sciencedirect.com

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

G Salles, N Mounier, S de Guibert… - Blood, The Journal …, 2008 - ashpublications.org
The FL2000 study was undertaken to evaluate the combination of the anti-CD20 monoclonal
antibody rituximab with chemotherapy plus interferon in the first-line treatment of follicular …
被引用次数：409 相关文章 所有 12 个版本
[PDF] researchgate.net

Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.

GA Salles, JF Seymour, P Feugier, F Offner… - Journal of Clinical …, 2010 - ascopubs.org
8004 Background: The GELA sponsored intergroup PRIMA Phase III study investigated 2
years of rituximab (R) maintenance in follicular lymphoma (FL) patients responding to first …
被引用次数：80 相关文章 所有 4 个版本

Rituximab Added αIFN+ CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 …

GA Salles, C Foussard, M Nicolas, M Franck, D Chantal… - 2004 - ashpublications.org
The monoclonal anti-CD20 antibody rituximab has been shown to induce a high response
rate in follicular lymphoma patients and to improve the outcome when associated with CVP …
被引用次数：67 相关文章 所有 2 个版本
[HTML] nih.gov

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup …

MHJ Van Oers, M Van Glabbeke, L Giurgea… - Journal of clinical …, 2010 - ascopubs.org
Purpose In 2006, we published the results of the European Organisation for Research and
Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission …
被引用次数：377 相关文章 所有 10 个版本